News Sentiment

IVVD sentiment intelligence

Invivyd Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.78 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-12.4% over one week, +1.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Here's Why We're Not Too Worried About Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Market Reaction

Price moving ahead of tone

57/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -12.4% Price reacting lower
Trend fit Trend inactive 1.7% over four weeks
Fair value -51.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 34
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 8
TradingView 7
simplywall.st 5
MT Newswires 3
www.marketscreener.com 3
The Globe and Mail 2
ad-hoc-news.de 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 19
Analyst action 6
Regulatory and legal 2
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
www.marketscreener.com Direct company coverage

Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Biotechnology Select Industry Index

Invivyd, Inc. (NasdaqGM: IVVD) has been removed from the S&P Biotechnology Select Industry Index. This news follows several recent updates from the company, including the completion of enrollment in its Phase 3 LIBERTY clinical trial for its VYD2311 antibody against COVID-19. Inv

Tone
Negative 29/100
Event
Market update
Published
22 Jun 2026 01:40
Source
www.marketscreener.com
Insider Monkey Direct company coverage

Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311

Invivyd Inc. (NASDAQ: IVVD) has dosed the first participants in its LIBERTY Phase 3 clinical trial for VYD2311, a monoclonal antibody candidate for COVID-19 prevention. This study will compare VYD2311's safety and tolerability against mRNA COVID-19 vaccines in approximately 210 h

Tone
Positive 74/100
Event
Market update
Published
19 Jun 2026 07:14
Source
Insider Monkey
TradingKey Direct company coverage

Invivyd Inc (IVVD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Invivyd Inc (IVVD) has an earnings forecast score of 8.67, ranking 13th in the Pharmaceuticals industry. Analysts have set an average price target of $10.00 for IVVD, with most recommending a "Buy" trend. The company's expected revenue for the next quarter is $14.40 million, and

Tone
Positive 79/100
Event
Earnings
Published
18 Jun 2026 10:10
Source
TradingKey